Strides Pharma Science informs about updates

23 Dec 2023 Evaluate

In continuation to Press Release dated July 4, 2023, and intimation dated December 1, 2023, Strides Pharma Science has informed that Stelis Biopharma, an associate company of Strides, has provided the following update about the transaction with Syngene to transfer Stelis’ Unit 3 multi-modal facility in Bengaluru: As informed vide the December 1, 2023, announcement, gross consideration for the transaction was INR 617 crores. Post certain adjustments, the net consideration receivable was INR 563.2 crores. On December 1, 2023, Stelis received INR 395 crores. Post completion of certain post-closing actions and final adjustments, Stelis has further received INR 158.2 crores on December 22, 2023. Syngene is withholding INR 10 crores, which shall be released post fulfilment of few additional conditions by Stelis.

The above information is a part of company’s filings submitted to BSE.


Strides Pharma Scien Share Price

679.55 -4.75 (-0.69%)
23-Dec-2024 10:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1815.00
Dr. Reddys Lab 1351.75
Cipla 1476.25
Lupin 2172.15
Zydus Lifesciences 974.95
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.